Rimonabant Clinical Study

What is Acomplia? How Acomplia Works? Acomplia Diet Drug Acomplia and Smoking

Patients treated for one year with rimonabant 20 mg per day lost 8.6 kg (almost 20 lbs.) vs. a loss of only 2.3 kg (5 lbs.) on placebo (p<0.001). Nearly 75% (p<0.001 vs. placebo) of patients treated for one year with ACOMPLIA(TM) 20 mg lost over 5% of their body weight as compared to 41.8% (p = 0.002 vs. placebo) of patients on ACOMPLIA(TM) 5 mg and 27.6% of patients in the placebo group. Moreover, 44.3% (p<0.001 vs. placebo) lost more than 10% of their body weight when treated for one year with ACOMPLIA(TM) 20 mg vs. 16.3% of patients on ACOMPLIA(TM) 5 mg or 10.3% of patients on placebo. In addition to weight loss, RIO-Lipids were designed to assess a number of associated important cardiovascular risk factors. All improvements in risk factors were statistically significant vs. the control group. In fact, the number of patients diagnosed as having metabolic syndrome1 at baseline (52.9%) was reduced by half (25.8%) after treatment with ACOMPLIA(TM) 20 mg (p<0.0001 compared to placebo). Study findings for rimonabant 20 mg include:

Waist circumference reduction of 9.1 cm (3.5 inches) in patients treated for a year (completers) with rimonabant 20 mg (p<0.001 vs. placebo).

Average increase of 23% in HDL-cholesterol in completers (p<0.001 vs. placebo).

Average reduction of 15% in triglycerides in completers (p<0.001 vs. placebo).

A positive shift in LDL particle size, with a reduction (p=0.002 vs. placebo) in the proportion of smaller dense atherogenic LDL particles, which are associated with cardiovascular risk, and an increase (p<0.001 vs. placebo) in the proportion of larger, less atherogenic LDL particles.